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near-infrared techniques has been proposed (2, 3 (22) or by intraperitoneal injection (23) , respec¬ tively, of glucose. The sensor response is measured at t = 0 (baseline) and again at a plateau of >5 min after the effect of the infusion is seen. At each of these points, the concentration of blood glucose is measured by using, e.g., the Beckman Analyzer or a self-monitoring strip. From this information, one can then establish the slope (sensitivity) and the intercept (background current) (24) . This procedure provides a reliable calibration curve without having to assume that the in vitro and in vivo responses are the same. This procedure has been described elsewhere (18, 24) .
Long-term sensor response has been evaluated in rats over the first 10 days after implantation (23) . When the sensor is initially implanted, there is a period of 2-4 h during which the sensor response stabilizes. From day 1 to day 10, there is essentially no change in either the sensitivity or the apparent response time of the sensors (n = 7). We consider this an important finding and suggest that previous observations led to overly pessi¬ mistic conclusions. The small size of this sensor and the minimal tissue damage caused by its implantation may contribute to its superior performance.
We evaluated the performance of the sensors (23) after 10 days, using the error grid analysis method of Clarke et al. (25) shown in Figure 4 (n = 101) (27) Clearly, if reliable, low-cost, noninvasive sensors can be developed, they will be the approach of choice. In the interim, minimally invasive devices may fill a critical gap.
